Vaxart, Inc. (VXRT) |
|
0.754 0.004 (0.53%)
|
09-29 16:00 |
|
Open: |
0.76 |
Pre. Close: |
0.75 |
|
High:
|
0.7699 |
Low:
|
0.7111 |
|
Volume:
|
485,919 |
Market Cap:
|
115(M) |
|
|
|
Technical analysis |
as of: 2023-09-29 4:31:12 PM |
|
Short-term rate:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
|
Mid-term rate:
|
  |
| Target: |
Six months: 0.91 One year: 0.99 |
| Support: |
Support1: 0.67 Support2: 0.55 |
| Resistance: |
Resistance1: 0.78 Resistance2: 0.85 |
| Pivot: |
0.73  |
| Moving Average: |
MA(5): 0.73 MA(20): 0.75
MA(100): 0.87 MA(250): 1 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 47.2 %D(3): 36.9 |
| RSI: |
RSI(14): 50.7 |
| 52-week: |
High: 2.25 Low: 0.56 |
| Average Vol(K): |
3-Month: 992 (K) 10-Days: 579 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ VXRT ] has closed below upper band by 30.4%. Bollinger Bands are 69.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.77 - 0.77 |
0.77 - 0.78 |
|
Low:
|
0.7 - 0.71 |
0.71 - 0.71 |
|
Close:
|
0.75 - 0.75 |
0.75 - 0.76 |
|
Company Description |
|
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California. |
Headline News |
Thu, 21 Sep 2023
Vaxart to Participate in Fireside Chat at 2023 Cantor Global ... - GlobeNewswire
Thu, 21 Sep 2023
Vaxart, Inc. –Vaxart to Participate in Fireside Chat at 2023 Cantor ... - Vaxart, Inc.
Wed, 06 Sep 2023
Vaxart, Inc. –Vaxart Announces Topline Data from the Phase 2 ... - Vaxart, Inc.
Sat, 05 Aug 2023
Vaxart, Inc. (NASDAQ:VXRT) Q2 2023 Earnings Call Transcript - Yahoo Finance
Thu, 27 Jul 2023
Vaxart, Inc. –Vaxart to Host Second Quarter 2023 Business Update ... - Vaxart, Inc.
Thu, 06 Jul 2023
Vaxart, Inc. –Vaxart Announces Positive Preliminary Topline Data ... - Vaxart, Inc.
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
152 (M) |
|
% Held by Insiders
|
1.5104e+008 (%) |
|
% Held by Institutions
|
0.7 (%) |
|
Shares Short
|
18,610 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-9.725e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-5 |
|
Return on Assets (ttm)
|
106.3 |
|
Return on Equity (ttm)
|
-43.2 |
|
Qtrly Rev. Growth
|
2.06e+006 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
-138.22 |
|
EBITDA (p.s.)
|
-1.26484e+008 |
|
Qtrly Earnings Growth
|
-0.8 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-86 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.01 |
|
Price to Cash Flow
|
0.86 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
1.647e+007 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2023-12-19 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
